Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Post by C10H12N2on May 21, 2022 3:39am
325 Views
Post# 34700134

COVID Breathalyzer

COVID Breathalyzer UNT built a breathalyzer that detects COVID. A Frisco company just got FDA approval to put it to work. How does the device work, exactly? Verbeck explained that the technology mimics the carbon filter in your refrigerator. Carbon is very good at capturing organics and getting them out of your water, Verbeck said. So, think of it as exactly the same sort of process. Weve sort of a carbon substrate and it is a carbon substrate, but its got some extra things in it that turns to the chemistry that youre interested in looking at. So, when youre in a disease state like COVID, your respiratory cells die. They go apoptotic. Which is just a fancy word for cell death. When those cells die, Verbeck said, small organic compounds are released that are unique to COVID. Those organic molecules are the ones that were capturing, and re-releasing back into the instruments, Verbeck said. So, thats called pre-concentrating. So, we just take it, we concentrate onto the substrate like a carbon filter and then we evacuate it, heat it up and off comes the volatile organic compounds that were interested in identifying. So, it takes a small amount of air to detect these organic compounds. https://dentonrc.com/business/unt-built-a-breathalyzer-that-detects-covid-a-frisco-company-just-got-fda-approval-to/article_a569a515-777c-5ee9-8e40-8fa052e535e3.html Once upon a time...there was a FAIMS device. A device aimed at detecting diseases or anything else Scientists/Lab Rats wanted to chase after. Then along came Christopher Moreau and the rest of the FAIMS story is history. The End
<< Previous
Bullboard Posts
Next >>